Press Releases
Aug. 28, 2017 biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
New Board nominees include accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc. biOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017
Aug. 21, 2017 biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer
Williams bring significant experience in working with both large, multinational pharmaceutical companies & start-up biotechnology alliances
Jun. 26, 2017 biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, London will have responsibility for leading all external communications, corporate visibility, brand-building,… Read more »
Jun. 15, 2017 biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally. The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The… Read more »
Jun. 14, 2017 biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) Dr. Mark Day, chief executive officer, has issued a message to shareholders detailing plans for the advancement of the Transcend Platform and the company’s in-house programs. To the Shareholders of biOasis Technologies Inc.: As the new CEO of biOasis, I am delighted to send my first message… Read more »
Jun. 8, 2017 biOasis to Present at The Global Chinese Financial Forum – Shanghai Conference 2017
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day. Dr. Day’s presentation,… Read more »
Jun. 4, 2017 biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07–10, 2017. Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets… Read more »
May. 16, 2017 biOasis Announces the Engagement of Mackie Research to Provide Market Making Services
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”), is pleased to announce that, subject to regulatory approval, it has retained Mackie Research Capital Corporation (“Mackie Research”) to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange… Read more »
Apr. 24, 2017 BIOASIS ANNOUNCES GRANT OF STOCK OPTIONS AND RESTRICTED STOCK UNITS
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that pursuant to the terms of its stock option plan (the “Option Plan”) and restricted stock units plan (the “RSU Plan”), the Company has granted a total of 2,377,478 stock options and 225,000 Restricted Share Units (RSUs) to its officers,… Read more »
biOasis Announces Investor Relations Service Agreement
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) The Company announces that it has entered into an investor relations agreement (“Agreement”) with 551943 Alberta Ltd., operating as Colwell Capital Corp (“Colwell”), for a maximum term of twelve months commencing April 24, 2017. The Company will pay Colwell $4,000 per month and will… Read more »